Biogen Inc. (BIIB)
Biogen Inc. (BIIB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Biogen Inc. (BIIB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise
Biogen (BIIB) is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer's therapies, driving improved mix quality. BIIB's 2025 growth products generated $3.3B, offsetting MS declines; non-GAAP EPS exceeded guidance at $15.28, reflecting strong cost discipline and operational execution. Despite a guided mid-single-digit revenue decline in 2026, BIIB maintains robust earnings power, with key catalysts, including Leqembi expansion and potential high-dose Spinraza approval.
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
BIIB Beats on Q4 Earnings & Sales, Stock Gains on Upbeat '26 EPS View
Biogen tops Q4 earnings and sales estimates, and shares rise after the company issues an encouraging 2026 adjusted EPS outlook despite revenue pressure.
Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Top Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.61 per share. This compares to earnings of $3.44 per share a year ago.
Biogen forecasts annual profit above estimates as Leqembi sales pick up
Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimer's treatment Leqembi as older multiple sclerosis drugs battle pressure from cheaper versions.
These Are The Worst 25 Stocks to Own in February
It's been an interesting start to the year, with plenty of geopolitical developments for investors to unpack.
